Back to Directory
Pegvisomant
Performance & EnduranceGH receptor antagonist for acromegaly, blocks growth hormone action.
Key Benefits
- ✓Treats acromegaly
- ✓Normalizes IGF-1
- ✓Blocks GH receptor
- ✓When somatostatin analogs insufficient
- ✓No tumor shrinkage
Dosing Information
Dosage Range
10-30 mg
Frequency
Once daily
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection daily. Dose titrated to normalize IGF-1 levels. Requires monitoring of liver function and IGF-1. Prescription only.
About Pegvisomant
Pegvisomant (Somavert) is a PEGylated growth hormone analog that acts as a GH receptor antagonist. It blocks growth hormone signaling at the receptor level, lowering IGF-1 without reducing GH secretion. FDA-approved for acromegaly.
Research Notes
FDA-approved in 2003 for acromegaly. Unique mechanism blocking GH receptor. Highly effective at normalizing IGF-1. Used when somatostatin analogs insufficient. Requires monitoring.
Potential Side Effects
- •Injection site reactions
- •Liver enzyme elevations
- •Flu-like symptoms
- •Tumor growth possible (no shrinkage)
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.